We showed using a cell-based reporter assay that IDH3 activity is reduced by >50% following HSP90 inhibition in HT29 cells, as well as in two other cell lines—HCT116 colon carcinoma, and BT474 breast ductal carcinoma (Fig. 6B). This evidence concerns the gene HSP90AB1 and breast ductal adenocarcinoma.